As of September 30, cash, cash equivalents and marketable securities were $187.3M as compared with $166M as of December 31, 2021. The company said, "The third quarter marked an exciting period for Terns, as we continued to accelerate development of our three lead programs in indications with large unmet need. With the completion of our $65 million financing in August, we are well-positioned to advance TERN-701 in CML and TERN-601 in obesity into the clinic in the United States in 2023. We also look forward to top-line data from the Phase 2a DUET trial evaluating TERN-501 monotherapy and in combination with TERN-101, the first trial to assess both THR-beta and FXR agonists in NASH, in the second half of 2023. We look forward to continued momentum in 2023 and multiple important milestones for Terns’ product candidates next year."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on TERN:
- Terns Pharmaceuticals highlights results from Phase 1 trial of TERN-501
- Terns Pharmaceuticals Highlights Results from Phase 1 Clinical Trial of TERN-501 at AASLD The Liver Meeting® 2022
- Terns Pharmaceuticals to Present Positive Clinical Data in NASH at AASLD The Liver Meeting® 2022
- JPMorgan Euro pharma and biotech analysts hold analyst/industry conference call
- Terns Pharmaceuticals to Present at the H. C. Wainwright 6th Annual NASH Investor Conference